ITM Setback Highlights Challenges Of Making Radiopharmaceuticals
The German firm has received a complete response letter from the US FDA for its GEP-NET product due to manufacturing issues but remains confident of approval.
Scrip - August 12, 2026

Speed to Scale: How India’s Pharma Market Is Minting Billion-Rupee Brands
More pharma brands in India ranging from in-licensed Chinese cancer therapies to cough and cold medications are crossing the INR100 crore sales threshold, with some doing so faster than ever before. Experts discuss the trend and also what Mounjaro's extraordinary market entry reveals.
Scrip - August 12, 2026

Alcon’s New-Product Wave Carries Q2 As It Walks Away From Accommodating IOL Bet
UNITY surgical systems, PanOptix Pro and a fast-ramping dry-eye franchise drove 7% constant-currency growth in the second quarter — even as Alcon took a $402m charge to discontinue its PowerVision accommodating lens programs and struck a light-adjustable IOL collaboration with RxSight.
Medtech Insight - August 12, 2026

J&J Bets on Outpatient Ablation Boom With ACCESS GPO Electrophysiology Deal
J&J has bundled its full electrophysiology technology stack into a single GPO agreement with ACCESS, giving physician-led ambulatory surgery centers a coordinated route to mapping, imaging and dual-energy ablation as outpatient cardiac care volume grows.
Medtech Insight - August 12, 2026

Hikma Delivers More Profit From Modest Sales Growth
The success detailed in the UK-based Hikma's H1 earnings report acts as a lesson for industry with a notably impressive operating leverage despite pricing erosions and other market challenges.
Generics Bulletin - August 12, 2026

Amneal’s $1bn Kashiv Acquisition Crosses The Finish Line
Amneal has completed its acquisition of Kashiv BioSciences, creating what it calls one of the industry's few fully integrated biosimilar platforms.
Generics Bulletin - August 12, 2026

Aurobindo Claims 5-7 Year Headstart With A1 Biochem, Lannett Acquisitions
The acquisition of US-based Lannett and India’s A1 Biochem, that has a US lab, have helped Aurobindo Pharma leapfrog onshoring and R&D capability scale-ups by five to seven years, giving it the confidence to handle mandatory US onshoring if required.
Generics Bulletin - August 12, 2026

Towa’s Core Generics And European Growth Outrun Fresh Sunsho Weakness
Japanese generics player Towa has kept its full-year guidance intact as higher domestic volumes and European growth offset further deterioration at its impaired Sunsho business.
Generics Bulletin - August 12, 2026

Samsung Bioepis Breaks Korean Ground For Keytruda
Samsung Bioepis has filed SB27 for approval in South Korea across 16 Keytruda indications, backed by successful Phase I and III trials, as rival pembrolizumab developers increasingly streamline their clinical programs.
Generics Bulletin - August 12, 2026

Eric Green’s Vision For Trace Neuroscience
Eric Green, CEO and co-founder of Trace Neuroscience, shared the progress his company has made — and the potential he sees — since its founding in 2024.
In Vivo - August 12, 2026

EU’s AI Act Climbdown Raises Stakes For MDR Revisions
MDR/IVDR simplifications are finally on the table, but differing stakeholder views and AI Act walkbacks cast doubt on their future.
Medtech Insight - August 12, 2026

Sanofi’s Bilingual Scientist: A Workforce Rebuilt Around AI
The company says it has cut research cycle times in half and wants to double its molecule output. Its new CEO is cutting late-stage assets and raising the bar for what advances – which makes the workforce it is building the bet that must pay off.
In Vivo - August 12, 2026

Asia-Pacific’s Medtech Pivot: From Factory Floor To Innovation Engine
A new Bain report says Asia-Pacific has shifted from medtech's factory floor to a genuine innovation source — 36% of global device research, two-thirds of patent filings, 30% of FDA 510(k) clearances. But a <5% share of FDA De Novo authorizations shows how far the region still has to climb.
Medtech Insight - August 12, 2026

Axing Self-Affirmed GRAS Pathway Without Notification Spurs Resource, Authority Questions
Demand on FDA resources and one-year deadline following effective date for notifications for ingredients already available self-GRAS but not notified could be more than FDA bargains for. Proposed rule also could order more than FDA has authority to do.
HBW Insight - August 12, 2026